肺表面活性物质预防早产儿RDS的临床观察  

CLINNICAL STUDY OF PROPHYLACTIC SURFACTANT REPLACEMENT THERAPY IN PRETERM INFANTS WITH RESPIRATORY DISTRESS SYNDROM (RDS)

作　　者：王莹[1] 马雅玲[1] 张巍[1] 

机构地区：[1]首都医科大学附属北京妇产医院新生儿科,100026

出　　处：《新生儿科杂志》2004年第4期148-151,共4页The Journal of Neonatology

摘　　要：目的 探讨肺表面活性物质(PS)预防用药对预防早产儿呼吸窘迫综合征(RDS)及改善早产儿预后的可行性。方法 我院胎龄≤32W的早产儿12例,于生后预防应用PS(预防组);同期确诊为RDS 17例应用呼吸机和PS(治疗组),比例两RDS发生率、呼吸机参数、并发症及预后。结果 预防组RDS发生3例,发生率为25％,低于我院同期收治的≤32W早产儿RDS发生率(43％);预防组RDS 3例均为Ⅱ期,治疗组Ⅲ期、Ⅳ为52.9％(9/17)。预防组上呼吸机所需压力明显低于治疗组,(P<0.05);肺炎、感染、颅内出血等合并症有下降趋势;未有气漏及BPD的发生。结论 PS预防用药可降低早产儿RDS发生率及减轻发病程度,减少呼吸机的应用,减少并发症,改善早产儿预后。To study the clinical value of prophylactic surfactant replacement therapy in RDS preterm newborn and improvement in the prognosis of survival. Methods Twelve newborns of ≤ 32 weeks' gestation age in our hospital received the prophylactic surfactant after delivery (the prophylaxis group-A); at the same time, 17 preterm newborns suffered form RDS required mechanical ventilation and pul-monary surfactant therapy (the treatment group-B) . Compared incidence of RDS, the parameters of ventilator, complications and outcome. Results The incidence of RDS in group A was 25% . It was signifi-cantly lower than that of RDS rate 43% of total preterm newborns(≤32 weeks)at our hospital. All 3 RDS cases in group A were Ⅱ phase, 9 RDS cases of 17 infants in group B were Ⅲ or Ⅳ phase, incidence was 52.9% . Pressure parameters in group A was statistically lower than that of group E(P < 0.05). There was downward trend in group A in complications such as pneumonia, infection, intracrani-al hemorrhage, etc. No pneumothorax and bronchopulmonary dysplasia happened. Conclusion Prophylactic surfactant usage in preterm infants can decrease the incidence and severity of RDS, ventilator set-tings and complications, as well as can improve the prognosis of survivors.

关 键 词：早产儿 RDS 呼吸机 并发症 发生率 治疗组 肺表面活性物质 结论 比例 目的 

分 类 号：R722.6[医药卫生—儿科]